![Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire](https://mms.businesswire.com/media/20191213005405/en/763006/5/4165450_121319_SABCS_2019_CONTROL_P5-14_Chan__poster_12-Dec-2019_FINAL.jpg)
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
![Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | BioSpace Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | BioSpace](https://mms.businesswire.com/media/20191211005896/en/762417/4/Untitled-1.jpg)
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | BioSpace
![Puma Biotechnology Presents P-II (SUMMIT) Basket Trial Results of Neratinib for EGFR Exon 18-Mutant NSCLC at EORTC/NCI/AACR 2022 Puma Biotechnology Presents P-II (SUMMIT) Basket Trial Results of Neratinib for EGFR Exon 18-Mutant NSCLC at EORTC/NCI/AACR 2022](https://pharmashots.com/public/images/20221028165227_original_6.webp)
Puma Biotechnology Presents P-II (SUMMIT) Basket Trial Results of Neratinib for EGFR Exon 18-Mutant NSCLC at EORTC/NCI/AACR 2022
![Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer | Business Wire Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer | Business Wire](https://mms.businesswire.com/media/20231211278700/en/1964518/23/041118_Puma_Logo_-_image002.jpg)
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer | Business Wire
Oxford Psychiatry on X: "Exciting developments on the new PUMA project with investigators holding their first meeting this week. PUMA, funded by @wellcome, is a multi-arm multi-stage (MAMS) platform trial for early
![RE:JERSEY – PUMA trials Garment-to-Garment Recycling in Circularity Project, using old Football Kits to produce new ones | PUMA® RE:JERSEY – PUMA trials Garment-to-Garment Recycling in Circularity Project, using old Football Kits to produce new ones | PUMA®](https://about.puma.com/sites/default/files/styles/dd_hero_wide/public/media/news/images/64abea541cc15.jpg?itok=FoIUGrPp)
RE:JERSEY – PUMA trials Garment-to-Garment Recycling in Circularity Project, using old Football Kits to produce new ones | PUMA®
![Illustration of the four biliary drainage procedures in the PUMa trial.... | Download Scientific Diagram Illustration of the four biliary drainage procedures in the PUMa trial.... | Download Scientific Diagram](https://www.researchgate.net/publication/364824198/figure/fig1/AS:11431281093330449@1667203551163/Illustration-of-the-four-biliary-drainage-procedures-in-the-PUMa-trial-1A-PTBD-with.jpg)